{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"120","value":"364"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"OG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"paramType":"MEAN","populationDescription":"Cohort 2 pharmacokinetic (PK) evaluable population was defined as participants who received any dose of atezolizumab treatment and had PK data at timepoints that were sufficient to determine PK parameters. Here, number of participants analyzed = participants who were evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hours) and 30 minutes post-dose on Day 1 of Cycle 1 (Cycle length = 21 days)","title":"Maximum Serum Concentration (Cmax) of Atezolizumab","type":"SECONDARY","unitOfMeasure":"microgram(s)/milliliter (mcg/mL)"}